Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab with Rapamycin in HER2+ Metastatic Breast Cancer
NCT04736589Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of inetetamab in breast cancer, sponsored by Peking Union Medical College. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04736589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736589.